Fairvalue-Calculator Fairvalue-Calculator
EN DE

Arterra Bioscience S.p.A (ARBS) Fair Value & Analysis

Healthcare · IT · Market cap €18.4M

Price€2.78
Fair Value€5.24
Upside+88.5%
Quality95/100
Evidence: High Range €3.32 – €7.22

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Arterra Bioscience S.p.A (ARBS) currently trades at €2.78, while our model-based Fair Value estimate is €5.24 — implying the stock looks roughly 88.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions. The company develops technological platforms, extraction processes, and raw materials for use in the cosmetics, agriculture, and nutraceutics sectors. Arterra Bioscience S.p.A. was founded in 2003 and is based in Napoli, Italy.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Arterra Bioscience S.p.A (ARBS) undervalued?
As of Jun 25, 2026, our model estimates a fair value of €5.24 versus a price of €2.78 — about +88% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ARBS?
Our 21-model fair value for Arterra Bioscience S.p.A is €5.24 (as of Jun 25, 2026), built from audited fundamentals. The current price is €2.78.
What is the quality score of ARBS?
Arterra Bioscience S.p.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.